Servier and Neurochlore announce the main results of the two phase 3 clinical studies assessing bumetanide in the treatment of Autism Spectrum Disorders in children and adolescents

Despite hundreds of children successfully treated in phase 2 and pilot trials around the world, the failure of phase 3 with Servier illustrates the difficulty of developing a universal treatment for autism.

See the Press Release :

Découvrez tous les sites de Yehezkel Ben-Ari/Discover all Yehezkel Ben-Ari websites

Le Blog de Ben-Ari
B&A Biomedical
B&A Oncomedical